These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 22118048)

  • 21. Es nucleoside transporter content of acute leukemia cells: role in cell sensitivity to cytarabine (araC).
    Gati WP; Paterson AR; Belch AR; Chlumecky V; Larratt LM; Mant MJ; Turner AR
    Leuk Lymphoma; 1998 Dec; 32(1-2):45-54. PubMed ID: 10037000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients.
    Gamazon ER; Lamba JK; Pounds S; Stark AL; Wheeler HE; Cao X; Im HK; Mitra AK; Rubnitz JE; Ribeiro RC; Raimondi S; Campana D; Crews KR; Wong SS; Welsh M; Hulur I; Gorsic L; Hartford CM; Zhang W; Cox NJ; Dolan ME
    Blood; 2013 May; 121(21):4366-76. PubMed ID: 23538338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNAs Mediated Regulation of Expression of Nucleoside Analog Pathway Genes in Acute Myeloid Leukemia.
    Bhise NS; Elsayed AH; Cao X; Pounds S; Lamba JK
    Genes (Basel); 2019 Apr; 10(4):. PubMed ID: 31022985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Absence of mutations in the deoxycytidine kinase (dCK) gene in patients with relapsed and/or refractory acute myeloid leukemia (AML).
    van den Heuvel-Eibrink MM; Wiemer EA; Kuijpers M; Pieters R; Sonneveld P
    Leukemia; 2001 May; 15(5):855-6. PubMed ID: 11368449
    [No Abstract]   [Full Text] [Related]  

  • 25. A microarray study of altered gene expression after cytarabine resistance in acute myeloid leukemia.
    Yin B; Tsai ML; Hasz DE; Rathe SK; Le Beau MM; Largaespada DA
    Leukemia; 2007 May; 21(5):1093-7. PubMed ID: 17301810
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of genetic alterations of cytarabine- metabolizing enzymes in childhood acute lymphoblastic leukemia.
    Banklau C; Jindadamrongwech S; Sawangpanich R; Apibal S; Hongeng S; Paisooksantivatana K; Pakakasama S
    Hematol Oncol Stem Cell Ther; 2010; 3(3):103-8. PubMed ID: 20890066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells.
    Song JH; Kim SH; Kweon SH; Lee TH; Kim HJ; Kim HJ; Kim TS
    Int J Oncol; 2009 Apr; 34(4):1165-71. PubMed ID: 19287976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia.
    Homminga I; Zwaan CM; Manz CY; Parker C; Bantia S; Smits WK; Higginbotham F; Pieters R; Meijerink JP
    Blood; 2011 Aug; 118(8):2184-90. PubMed ID: 21730354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of the nucleoside transporters hENT1 (SLC29) and hCNT1 (SLC28) in pediatric acute myeloid leukemia.
    Jaramillo AC; Hubeek I; Broekhuizen R; Pastor-Anglada M; Kaspers GJL; Jansen G; Cloos J; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2020; 39(10-12):1379-1388. PubMed ID: 32312148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression.
    Jin G; Matsushita H; Asai S; Tsukamoto H; Ono R; Nosaka T; Yahata T; Takahashi S; Miyachi H
    Biochem Biophys Res Commun; 2009 Dec; 390(3):1001-6. PubMed ID: 19853583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia.
    Kim JH; Lee C; Cheong HS; Koh Y; Ahn KS; Kim HL; Shin HD; Yoon SS
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):533-40. PubMed ID: 27422302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deoxycytidine kinase expression and activity in patients with resistant versus sensitive acute myeloid leukemia.
    Veuger MJ; Honders MW; Willemze R; Barge RM
    Eur J Haematol; 2002 Sep; 69(3):171-8. PubMed ID: 12406011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues.
    Drenberg CD; Gibson AA; Pounds SB; Shi L; Rhinehart DP; Li L; Hu S; Du G; Nies AT; Schwab M; Pabla N; Blum W; Gruber TA; Baker SD; Sparreboom A
    Cancer Res; 2017 Apr; 77(8):2102-2111. PubMed ID: 28209616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants.
    Lamba JK; Crews K; Pounds S; Schuetz EG; Gresham J; Gandhi V; Plunkett W; Rubnitz J; Ribeiro R
    J Pharmacol Exp Ther; 2007 Dec; 323(3):935-45. PubMed ID: 17855478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FMS-like tyrosine kinase 3 (FLT3) modulates key enzymes of nucleotide metabolism implicated in cytarabine responsiveness in pediatric acute leukemia.
    Perelló-Reus CM; Català A; Caviedes-Cárdenas L; Vega-García N; Camós M; Pérez-Torras S; Pastor-Anglada M
    Pharmacol Res; 2020 Jan; 151():104556. PubMed ID: 31778791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis.
    Magina KN; Pregartner G; Zebisch A; Wölfler A; Neumeister P; Greinix HT; Berghold A; Sill H
    Blood; 2017 Aug; 130(7):946-948. PubMed ID: 28679736
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical significance of in vivo cytarabine-induced gene expression signature in AML.
    Lamba JK; Pounds S; Cao X; Crews KR; Cogle CR; Bhise N; Raimondi SC; Downing JR; Baker SD; Ribeiro RC; Rubnitz JE
    Leuk Lymphoma; 2016; 57(4):909-20. PubMed ID: 26366682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia.
    Walter RB; Appelbaum FR; Estey EH
    Leukemia; 2021 Feb; 35(2):295-298. PubMed ID: 33328603
    [No Abstract]   [Full Text] [Related]  

  • 39. [Observation and care in high-dose cytarabine treatment of acute myelogenous leukemia].
    Xi YR; Tu YL; Zhao XH
    Zhonghua Hu Li Za Zhi; 1996 Nov; 31(11):653-5. PubMed ID: 9304928
    [No Abstract]   [Full Text] [Related]  

  • 40. Role of Genetic Polymorphisms of Deoxycytidine Kinase and Cytidine Deaminase to Predict Risk of Death in Children with Acute Myeloid Leukemia.
    Medina-Sanson A; Ramírez-Pacheco A; Moreno-Guerrero SS; Dorantes-Acosta EM; Sánchez-Preza M; Reyes-López A
    Biomed Res Int; 2015; 2015():309491. PubMed ID: 26090398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.